Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + lenvatinib or iparomlimab + tuvonralimab + axitinib-Tianjin Medical University Cancer Institute and Hospital-clear cell renal cell carcinoma
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen consists of QL1706 (a co-formulation of the PD-1 inhibitor iparomlimab and the CTLA-4 inhibitor tuvonralimab) administered in conjunction with a tyrosine kinase inhibitor (TKI), either lenvatinib or axitinib. QL1706, developed by Qilu Pharmaceutical using its Mab-Pair technology, provides dual immune checkpoint blockade to enhance T-cell anti-tumor activity. Lenvatinib (Eisai) and axitinib (Pfizer) are small-molecule inhibitors that target vascular endothelial growth factor receptors (VEGFR) to inhibit tumor angiogenesis and potentially modulate the tumor microenvironment. This specific regimen is being evaluated in a Phase II clinical trial (NCT06144125) sponsored by the Tianjin Medical University Cancer Institute and Hospital for patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after first-line systemic therapy.
- Brand names
- Lenvima
- Other names
- iparomlimab + tuvonralimab + lenvatinibiparomlimab + tuvonralimab + axitinibQL1706 + LenvatinibQL1706 + Axitinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + lenvatinib or iparomlimab + tuvonralimab + axitinib-Tianjin Medical University Cancer Institute and Hospital-clear cell renal cell carcinoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + lenvatinib or iparomlimab + tuvonralimab + axitinib-Tianjin Medical University Cancer Institute and Hospital-clear cell renal cell carcinoma.